Page 226 - Haematologica March 2020

C. Martín-Cortázar et al. References
1. FidlerIJ,KripkeML.Thechallengeoftarget- ing metastasis. Cancer Metastasis Rev. 2015;34(4):635-641.
2. Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol. 2004;24(4):395-404.
3. Kufe DW, Holland JF, Frei E, American Cancer Society. Cancer Medicine. 6th ed. Hamilton, Ont.; Lewiston, NY: BC Decker, 2003.
4. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786-801.
5. Mittal R, Patel AP, Debs LH, et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J Cell Physiol. 2016;231(12):2599-2621.
6. Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimen- sional amoeboid movement revisited. J Cell Biol. 2009;185(1):11-19.
7. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mecha- nisms. Nat Rev Cancer. 2003;3(5):362-374.
8. Ridley AJ. Life at the leading edge. Cell. 2011;145(7):1012-1022.
9. Vicente-Manzanares M, Webb DJ, Horwitz AR. Cell migration at a glance. J Cell Sci. 2005;118(Pt 21):4917-4919.
10. ParsonsJT,HorwitzAR,SchwartzMA.Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;11(9):633-643.
11. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10(11):778-790.
12. Wolf K, Muller R, Borgmann S, Brocker EB, Friedl P. Amoeboid shape change and con- tact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other pro- teases. Blood. 2003;102(9):3262-3269.
13. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transi- tion after blocking of pericellular proteoly- sis. J Cell Biol. 2003;160(2):267-277.
14. Michaelis UR. Mechanisms of endothelial cell migration. Cell Mol Life Sci. 2014;71(21):4131-4148.
15. LammermannT,SixtM.Mechanicalmodes of 'amoeboid' cell migration. Curr Opin Cell Biol. 2009;21(5):636-644.
16. Krummel MF, Macara I. Maintenance and modulation of T cell polarity. Nat Immunol. 2006;7(11):1143-1149.
17. Gomes ER, Jani S, Gundersen GG. Nuclear movement regulated by Cdc42, MRCK, myosin, and actin flow establishes MTOC polarization in migrating cells. Cell. 2005;121(3):451-463.
18. Jimenez PR, Martin-Cortazar C, Kourani O, et al. CDCA7 is a critical mediator of lym- phomagenesis that selectively regulates anchorage-independent growth. Haematologica. 2018;103(10):1669-1678.
19. Prescott JE, Osthus RC, Lee LA, et al. A novel c-Myc-responsive gene, JPO1, partici- pates in neoplastic transformation. J Biol Chem. 2001;276(51):48276-48284.
20. Jenness C, Giunta S, Muller MM, Kimura H, Muir TW, Funabiki H. HELLS and CDCA7 comprise a bipartite nucleosome remodel- ing complex defective in ICF syndrome. Proc Natl Acad Sci U S A. 2018;115(5):E876- E885.
21. Thijssen PE, Ito Y, Grillo G, et al. Mutations in CDCA7 and HELLS cause immunodefi- ciency-centromeric instability-facial anom- alies syndrome. Nat Commun. 2015;6:7870.
22. Gill RM, Gabor TV, Couzens AL, Scheid MP. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC- dependent apoptosis and transformation. Mol Cell Biol. 2013;33(3):498-513.
23. Osthus RC, Karim B, Prescott JE, et al. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. 2005;65(13):5620-5627.
24. Alvaro-Blanco J, Urso K, Chiodo Y, et al. MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. Nucleic Acids Res. 2017;45(17):9960-9975.
25. Campanero MR, Herrero A, Calvo V. The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. Oncogene. 2008;27(9):1263-1272.
26. Molina-Privado I, Jimenez PR, Montes- Moreno S, et al. E2F4 plays a key role in Burkitt lymphoma tumorigenesis. Leukemia. 2012;26(10):2277-2285.
27. Molina-Privado I, Rodriguez-Martinez M, Rebollo P, et al. E2F1 expression is deregulat- ed and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res. 2009;69(9):4052-4058.
28. Hruz T, Laule O, Szabo G, et al. Genevestigator v3: a reference expression database for the meta-analysis of transcrip- tomes. Adv Bioinformatics. 2008;2008: 420747.
29. Chen L, Groenewoud A, Tulotta C, et al. A zebrafish xenograft model for studying human cancer stem cells in distant metasta- sis and therapy response. Methods Cell Biol. 2017;138:471-496.
30. Arroyo AG, Garcia-Pardo A, Sanchez- Madrid F. A high affinity conformational state on VLA integrin heterodimers induced by an anti-beta 1 chain monoclonal anti- body. J Biol Chem. 1993;268(13):9863-9868.
31. Luque A, Gomez M, Puzon W, Takada Y, Sanchez-Madrid F, Cabanas C. Activated conformations of very late activation inte- grins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem. 1996;271(19):11067-
11075.
32. Foley KS, Young PW. The non-muscle func-
tions of actinins: an update. Biochem J.
2014;459(1):1-13.
33. Loirand G, Guerin P, Pacaud P. Rho kinases
in cardiovascular physiology and patho-
physiology. Circ Res. 2006;98(3):322-334. 34. Rydlova M, Holubec L, Jr., Ludvikova M, Jr., et al. Biological activity and clinical implica- tions of the matrix metalloproteinases.
Anticancer Res. 2008;28(2B):1389-1397.
35. Zhong Y, Lu YT, Sun Y, et al. Recent oppor- tunities in matrix metalloproteinase inhibitor drug design for cancer. Expert
Opin Drug Discov. 2018;13(1):75-87.
36. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell.
1998;94(3):353-362.
37. Madri JA, Graesser D. Cell migration in the
immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immunol. 2000;7(2-4):103-116.
38. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995;154(9):4379-4389.
39. Redondo-Munoz J, Jose Terol M, Garcia- Marco JA, Garcia-Pardo A. Matrix metallo- proteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood. 2008;111(1):383-386.
40. Vacca A, Ribatti D, Iurlaro M, et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res. 1998;28(1):55-68.
41. Bartlett MR, Underwood PA, Parish CR. Comparative analysis of the ability of leuco- cytes, endothelial cells and platelets to degrade the subendothelial basement mem- brane: evidence for cytokine dependence and detection of a novel sulfatase. Immunol Cell Biol. 1995;73(2):113-124.
42. Weissmann M, Arvatz G, Horowitz N, et al. Heparanase-neutralizing antibodies attenu- ate lymphoma tumor growth and metasta- sis. Proc Natl Acad Sci U S A. 2016;113(3):704-709.
43. Ivanoff J, Talme T, Sundqvist KG. The role of chemokines and extracellular matrix components in the migration of T lympho- cytes into three-dimensional substrata. Immunology. 2005;114(1):53-62.
44. Ye L, Li F, Song Y, et al. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer. Int J Cancer. 2018;143(10):2602-2613.
45. Otey CA, Carpen O. Alpha-actinin revisit- ed: a fresh look at an old player. Cell Motil Cytoskeleton. 2004;58(2):104-111.
46. Sjoblom B, Salmazo A, Djinovic-Carugo K. Alpha-actinin structure and regulation. Cell Mol Life Sci. 2008;65(17):2688-2701.
740
haematologica | 2020; 105(3)